ABOzymes is pioneering a transformative approach to blood and organ compatibility through its innovative enzymatic technology. The company focuses on converting various blood types into universal type O, which is crucial for blood transfusions and organ transplants. By utilizing enzymes to modify the antigens present on blood cell surfaces, ABOzymes aims to eliminate the traditional barriers associated with blood type matching. This advancement not only has the potential to double the supply of universally accepted O type blood but also significantly increases the number of viable organ donations, thereby reducing wait times for patients in need of transplants.

The technology developed by ABOzymes integrates seamlessly into existing blood processing and organ procurement workflows. Enzymes can be introduced during the collection of whole blood or red blood cells, as well as in preservation solutions used for organ perfusion. This innovative approach addresses the critical shortage of O type blood and the challenges faced in organ donation, ultimately prioritizing patient needs and enhancing the efficiency of healthcare systems. By transforming blood types and expanding donor compatibility, ABOzymes is set to revolutionize the landscape of transfusions and organ transplants, saving more lives and minimizing waste.

Canada

Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers to better prioritize patients by medical urgency, spend less on management and logistics and ultimately save more lives.

Avivo Biomedical

Company Details